Everest Medicines doses first patient in ASCEND Phase 2b trial of VIS-101 for wet AMD
Everest Medicines announced on 20 November 2026 that the first patient was treated in China in the 244-patient Phase 2b ASCEND trial comparing VIS-101 against 2 mg aflibercept in wet age-related macular degeneration, ahead of a planned 2027 global Phase 3 program.
Event / data period:
Published: · Updated:

Everest Medicines announced on 20 November 2026 from Shanghai that the first patient has been dosed in the ASCEND study, a randomized Phase 2b clinical trial evaluating its investigational ophthalmology candidate VIS-101 in wet age-related macular degeneration. The study is being conducted in China in partnership with Visara, Inc., a majority-owned ophthalmology subsidiary of NovaBridge Biosciences. Everest Medicines stated that the trial is designed to compare two dose levels of VIS-101 directly against aflibercept, an established anti-VEGF standard of care, to select dosing for a global Phase 3 program.
Registered on ClinicalTrials.gov as NCT07798375, ASCEND is a randomized, quadruple-masked, active-controlled, head-to-head Phase 2b trial planned to enrol approximately 244 treatment-naïve patients with wet age-related macular degeneration in China. Participants are randomized to receive either 6 mg VIS-101, 9 mg VIS-101 or 2 mg aflibercept. All treatment arms begin with three monthly loading injections, after which patients can be retreated up to Month 9 according to identical protocol-specified retreatment criteria across groups.
The trial's primary efficacy endpoint is the change in best-corrected visual acuity from baseline to Week 36 compared with aflibercept administered every eight weeks. Alongside visual acuity outcomes and safety monitoring, the ASCEND protocol is structured to assess initial treatment durability, including whether VIS-101 can sustain disease control across intervals of up to seven months following the three initial loading doses. Everest Medicines said findings from the dose-determining trial will guide dose selection for global Phase 3 development, which is planned to begin as early as 2027.
VIS-101, also identified in development records as AM712 or ASKG712, is a bispecific, tetravalent dual inhibitor targeting both vascular endothelial growth factor A and angiopoietin-2. The molecule is being developed for retinal vascular disorders including wet age-related macular degeneration, diabetic macular edema and retinal vein occlusion. According to Everest Medicines, its tetravalent molecular architecture provides additional binding sites intended to increase binding affinity and avidity against both targets to support rapid visual responses and longer intervals between intravitreal injections.
Prior to launching ASCEND, VIS-101 completed initial safety and dose-escalation studies in both the United States and China, followed by a randomized, dose-ranging Phase 2a study in China registered as NCT05456828. Everest Medicines reported that in the Phase 2a study, VIS-101 demonstrated rapid and durable responses alongside a favorable safety profile in wet age-related macular degeneration, with approximately 50 percent of patients in the 6 mg treatment-naïve cohort remaining retreatment-free six months after their final loading injection.
The commercial and regional development framework for VIS-101 rests on a licensing agreement signed on 30 October 2025 between Everest Medicines and Visara. Under that agreement, Everest acquired an exclusive license to develop, manufacture and commercialize VIS-101 across Greater China, Singapore, South Korea and selected Southeast Asian countries. Everest Medicines operates a commercial-scale manufacturing facility in Jiashan in Zhejiang Province, maintaining a good manufacturing practice quality system aligned with Chinese, European Union and World Health Organization standards.
In explaining the clinical rationale, Everest Medicines cited published epidemiological estimates indicating that wet age-related macular degeneration affects more than 20 million people worldwide. Within China, the company stated that the prevalent population living with age-related macular degeneration and diabetic macular edema exceeds 15 million people, with approximately 600,000 new cases emerging each year, while only about 500,000 patients currently receive active treatment. Frequent clinic visits for intravitreal eye injections remain a widely cited barrier to long-term adherence.
Everest Medicines chief executive officer Rogers Yongqing Luo said patients with wet age-related macular degeneration and other retinal vascular diseases continue to face a heavy treatment burden. He described dosing the first patient in ASCEND as an important step toward testing whether VIS-101 can deliver longer intervals between injections and sustained disease control compared with an established standard of care, adding that the company's regional clinical and commercial infrastructure across China and Asia will support development.
VIS-101 remains an investigational biologic without marketing authorization in any jurisdiction, and the announcement on 20 November 2026 marks the start of Phase 2b treatment rather than a readout of comparative efficacy. Whether the 6 mg or 9 mg regimen matches or improves upon aflibercept at Week 36 while maintaining safety and extended retreatment intervals will only become clear once the 244-patient cohort completes follow-up. Any Phase 3 initiation in 2027 remains contingent on ASCEND results and regulatory review.
Data
Key reported figures
Selected ASCEND Phase 2b trial parameters, Phase 2a durability data and regional wet AMD prevalence estimates cited by Everest Medicines.
- Planned enrolment in ASCEND Phase 2b wet AMD trial in China
- ≈244 patients
- 2026-11-20 · Target
- Primary efficacy endpoint assessment time in ASCEND
- 36 weeks
- 2026-11-20 · Observed
- Phase 2a 6 mg treatment-naïve cohort retreatment-free at 6 months
- ≈50 percent
- 2026-11-20 · Observed
- Estimated annual new AMD and DME cases in China
- ≈600,000 cases
- 2026-11-20 · Estimate
- Estimated AMD and DME patients currently receiving treatment in China
- ≈500,000 patients
- 2026-11-20 · Estimate
Methodology
Figures retain the source's stated trial design, population, scope and definitions. Targets and prevalence estimates are labeled by basis. No missing value is inferred.
Updated:
Subjects and places
Subject proposals
- HealthSuggested
- Preserved editorial category/topic; broad candidate onlywww.prnewswire.com ↗
Geographic references
Only source-provided geographic references are shown. Opening an external map is optional. Optional story maps use OpenStreetMap. Opening a map sends your IP address and this site’s address to the map provider; location data remains readable as text without loading the map.
- China · Place role: Coverage · Place type: Country or area · Location precision: RegionalEvidence
- Explicit preserved editorial country/region; no city or national centroid inferredwww.prnewswire.com ↗